ReviewDiagnostics (Basel, Switzerland)2025
Cardiovascular Prevention: Current Gaps and Future Directions.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Cardiovascular Risk Awareness Among Adults in the Northern Border Region of Saudi Arabia: A Cross-Sectional Study with Emphasis on Hypertension and Type 2 Diabetes.Diseases (Basel, Switzerland) · 2026Article
- Analysis of the Relationship of Glycated Hemoglobin with Subclinical Atherosclerosis and Arterial Stiffness in Non-Diabetic Patients: A Retrospective Study.Journal of clinical medicine · 2026Article
- Review
- Review
- The predictive value of combined assessment of estimated glucose disposal rate and non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for cardiovascular disease risk: a nationwide cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular Disease (CVD) remains the leading cause of morbidity and mortality worldwide. Despite significant advances in diagnosis and treatment, the global burden of CVD remains high, underscoring the crucial need for more effective and comprehensive prevention strategies. This narrative overview aims to critically evaluate the current pillars of cardiovascular prevention, identify the gaps in approaches and outline promising future directions. Challenges and barriers in lifestyle adherence and pharmacological management are addressed, while the increasing role of non-traditional and emerging risk factors is discussed. Future directions include maximizing the value of digital health to improve patient engagement and adherence, adopting precision medicine to refine risk stratification and implementing public health policies for population-level interventions. The optimization of cardiovascular prevention requires a multi-level approach that integrates clinical strategies with personalized solutions and environmental policies to ultimately reduce the global impact of CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.